WallStSmart

ResMed Inc (RMD)vsRetractable Technologies Inc (RVP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 14045% more annual revenue ($5.40B vs $38.16M). RMD leads profitability with a 27.5% profit margin vs -22.9%. RMD earns a higher WallStSmart Score of 70/100 (B).

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34

RVP

Hold

39

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Intrinsic value data unavailable for RVP.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

RVP2 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
73.2%10/10

Revenue surging 73.2% year-over-year

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

RVP4 concerns · Avg: 2.3/10
Market CapQuality
$24.25M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-10.8%2/10

ROE of -10.8% — below average capital efficiency

EPS GrowthGrowth
-66.7%2/10

Earnings declined 66.7%

Free Cash FlowQuality
$-1.35M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bull Case : RVP

The strongest argument for RVP centers on Price/Book, Revenue Growth. Revenue growth of 73.2% demonstrates continued momentum.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : RVP

The primary concerns for RVP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

RMD profiles as a mature stock while RVP is a hypergrowth play — different risk/reward profiles.

RVP carries more volatility with a beta of 1.14 — expect wider price swings.

RVP is growing revenue faster at 73.2% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 39/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Retractable Technologies Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States, the rest of North and South America, and internationally. The company is headquartered in Little Elm, Texas.

Want to dig deeper into these stocks?